Minoxidil: an underused vasodilator for resistant or severe hypertension.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert clinical commentary without systematic search methodology or original experimental data.
PubMed 15133413 · doi:10.1111/j.1524-6175.2004.03585.x
What was done
This paper is a narrative clinical review evaluating the pharmacology, therapeutic role, adverse effects, and co-administration requirements of minoxidil for resistant and severe hypertension.
What was found
The abstract reports no empirical numbers or quantitative effect sizes. It describes minoxidil as effective in reducing blood pressure when multidrug regimens have failed, but notes that its use is limited by reflex tachycardia, sodium and water retention, hypertrichosis, and infrequent pericardial effusion, necessitating co-prescription with a diuretic and a beta-blocker or alpha-beta blocker.
Why it matters
It outlines the practical clinical utility and safety precautions for using minoxidil as a salvage vasodilator in severe refractory hypertension, particularly in individuals with advanced renal disease.
Limits
The abstract contains no primary quantitative data, sample size, or systematic methodology. Being a narrative review, it relies on general clinical principles and expert opinion rather than controlled trial data.
Cited by
- supports Minoxidil functions as a potassium channel opener and when taken orally can cause pericardial effusion, water retention, and electrolyte dysregulation.